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metabolism of nervous cells, crosses the blood-brain barrier
(BBB) and the neuronal plasma membrane with difficulty,
and only using its specific transporter. In the hereditary con-
dition where the creatine transporter is defective (creatine
transporter deficiency) there is no creatine in the brain,
and administration of creatine is useless lacking the
transporter. The disease is severe and incurable. Creatine-
derived molecules that could cross BBB and plasma
membrane independently of the transporter might be useful
to cure this condition. Moreover, such molecules could be
useful also in stroke and other brain ischemic conditions.
In this paper, we investigated three creatine salts, creatine
ascorbate, creatine gluconate and creatine glucose. Of
these, creatine glucose was ineffective after transporter
block with guanidine acetic acid (GPA) administration. Crea-
tine ascorbate was not superior to creatine in increasing tis-
sue creatine and phosphocreatine content after transporter
impairment, however even after such impairment it delayed
synaptic failure during anoxia. Finally, creatine gluconate
was superior to creatine in increasing tissue content of cre-
atine after transporter block and slowed down PS disappear-
ance during anoxia, an effect that creatine did not have.
These findings suggest that coupling creatine to molecules
having a specific transporter may be a useful strategy in cre-
atine transporter deficiency. In particular, creatine ascorbate
has effects comparable to those of creatine in normal
conditions, while being superior to it under conditions of
missing or impaired creatine transporter.  2016 Thehttp://dx.doi.org/10.1016/j.neuroscience.2016.02.038
0306-4522/ 2016 The Authors. Published by Elsevier Ltd on behalf of IBRO.
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INTRODUCTION
Creatine or Methyl Guanidino-Acetic Acid is an amino
acid that is central to the energetic metabolism of the
cells, particularly those with high energy requirements
like neurons (Béard and Braissant, 2010). Inside the cells
creatine is reversibly phosphorylated to phosphocreatine,
with which it is in constant equilibrium. The functions of
this creatine/phosphocreatine system are twofold. Under
physiological conditions it moves ATP from the site
where it is synthesized (the mitochondrion) to the
cytoplasmic sites where it is utilized (mainly the plasma
Na/K-ATPase). Under pathological conditions of energy
deprivation, it provides rapidly available energy to replen-
ish failing energy reserves. The body, even the brain, can
synthesize creatine but is also takes it up with the diet. To
reach the brain, creatine synthesized by the body or taken
up with the diet must cross the blood-brain barrier (BBB),
and to do so it needs a specific transporter (creatine
transporter or CrT) codified by the gene SLC6A8
(Christie, 2007). Once across the BBB, it needs again
the same transporter to cross the cell plasma membrane
and enter brain neurons (Lunardi et al., 2006). Exogenous
creatine may be useful for human therapy in two main
disease groups:
1. Cerebral ischemia and stroke (Balestrino et al., 2002;
Prass et al., 2006; Perasso et al., 2013).
2. Hereditary diseases with primary deficiency of brain
creatine (Stockler, 1997). Among them, creatine can
be used to restore its brain content in those conditions
where its synthesis is impaired (GAMT or AGAT defi-
ciency), but it is not useful in the hereditary creatine
transporter deficiency (OMIM 300352) where cerebral
synthesis of creatine is not sufficient to provide normal
brain content. In the latter case, lacking the transporter
it cannot be taken up by the BBB nor by cerebral cells.
Thus, creatine transporter deficiency is currently incur-










Fig. 1. (a) Creatine gluconate, (b) Creatine ascorbate, (c) Creatine
glucose.
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transporter deficiency could be to modify the creatine
molecule in such a way as to create a molecular
structure that can cross the BBB and at the same time
maintain a biological activity similar to that of creatine
(Balestrino et al., 2002). While such molecules have
indeed been researched, even by our laboratory
(Perasso et al., 2008, 2009; Adriano et al., 2011; Enrico
et al., 2013), no fully satisfactory treatment is available.
For this reason, we shifted our attention to the formation
of creatine salts formed by two moieties, one of which is
a molecule that has its own transporter. In this way, the
salt may be transported across both BBB and cell plasma
membrane by the latter transporter, that is unimpaired by
creatine transporter deficiency. Once in the cells, the salts
should be split and free creatine should remain. These
compounds may therefore be useful for the treatment of
creatine transporter deficiency. Furthermore, they could
also be used to treat cerebral ischemia and stroke
(Perasso et al., 2013). Specifically, we tested three differ-
ent creatine derivatives: (1) a salt formed from creatine
and ascorbate (a molecule that has been before sug-
gested as a vector across the BBB – Dalpiaz et al.,
2005); (2) a salt formed from creatine and glucose; and
(3) a salt from creatine and D-gluconic acid (this latter
salt, commercially available, should use the glucose
transporter to cross the BBB).
As a model, we used mouse hippocampal slices.
Although no BBB obviously exists in this in vitro model,
creatine still needs its transporter to cross the neuronal
plasma membrane and enter cells, thus compounds’
efficacy under conditions of creatine transporter
impairment may be tested in this model (Lunardi et al.,
2006). As a gauge of efficacy, we tested the ability of cre-
atine and of creatine-derived compounds to:
1. Delay the disappearance of evoked electrical poten-
tials during anoxia, a well-known effect of creatine that
we used before in our research (Perasso et al., 2008)
and
2. Increase the tissue concentrations of creatine and
phosphocreatine.
We carried out the above investigations both under
control conditions and after pharmacological block of the
creatine transporter.RESULTS
Creatine-derived compounds
Creatine gluconate (Fig. 1a) and creatine glucose
(Fig. 1c) are two salts formed by creatine and D-gluconic
acid and by creatine and glucose, respectively. Creatine
ascorbate (Fig. 1b) is a salt formed by creatine and
ascorbic acid (Vitamin C). The creatine-ascorbate and
creatine glucose were synthesized following the method
described in the Experimental procedure. Creatine
gluconate is commercially available (see ‘‘Experimental
procedure” section).We analyzed these creatine derivatives in HPLC-MS
to certify the purity of the final products. We also
investigated the stability of these salts in saline solution.
We found that creatine glucose content is reduced to
about half after about 75 min (Fig. 2A). Creatine
ascorbate is reduced to about half after 40 min
(Fig. 2B). Creatine glucose is the most stable of the
three compounds, its content being reduced to half after
180 min. (Fig. 2C). Creatine monohydrate by contrast is
rather stable in an aqueous solution, at least for a few
hours (Adriano et al., 2011).
Effects on tissue concentrations of creatine and of
phosphocreatine
In these experiments, we tested creatine, creatine-
gluconate, creatine-ascorbate and creatine-glucose
under normal conditions and after block of the creatine
transporter to assess the tissue creatine and
phosphocreatine concentration.
Effects under normal conditions. Under control
conditions, i.e. in slices where the creatine transporter is
normally working, all compounds were able to increase
tissue creatine concentration, with no differences among
them (Fig. 3A). Moreover, all of them were also able to
increase phosphocreatine concentration except creatine
itself, which showed only a not significant trend toward
increase (Fig. 3B).
Fig. 2. Compound degradation in the aqueous incubation medium. In ordinate substance concentration, normalized as described in the
experimental procedures section. In abscissae time in minutes. Data are mean-relative standard deviation of three observations. (A) The original
creatine glucose content is reduced to about half after about 75 min. After 3 h, only 20% of the initial compound amount is still present. (B)
concentration of creatine ascorbate is reduced to about half after 40 min. After 3 h, only 5/7% of the initial compound amount is still present. (C)
creatine glucose is the most stable of the three compounds, content is reduced to half after 180 min. After 3 h, 60% of the initial compound amount is
still present.
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Fig. 3. Creatine and phosphocreatine content under conditions of
normally working transporter. CR= Creatine. Data are mean
± standard deviation. Asterisks show statistically significant differ-
ences with control group (p< 0.05, post hoc Dunn’s multiple
comparison test). N= 10 in all groups.
Fig. 4. Creatine and phosphocreatine content under conditions of
partially blocked transporter (GPA). CR= Creatine. Data are mean
± standard deviation. Asterisks show statistically significant differ-
ences with control group (p< 0.05, post hoc Dunn’s multiple
comparison test). N= 10 in all groups.
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block of the creatine transporter with guanidine acetic
acid (GPA) 10 mM, creatine, creatine-gluconate and
creatine-ascorbate increased the tissue content of
creatine, with creatine gluconate increasing tissue
creatine more than creatine itself (Fig. 4A). Creatine-
glucose was ineffective while only a slight increase was
observed with creatine-ascorbate (Fig. 4A). No molecule
was able to increase tissue content of phospho-creatine
in these experimental conditions (Fig. 4B).Effects on disappearance of evoked potentials during
anoxia
In these experiments, we tested creatine, creatine-
gluconate and creatine-ascorbate under normalconditions and after block of the creatine transporter to
evoke electrical potentials during anoxia. We were
discouraged from testing creatine-glucose by the fact
that the latter was ineffective in increasing creatine
content after transporter impairment (see above).Effects under normal conditions. Under baseline
conditions, both creatine ascorbate and creatine
gluconate were able to delay population spike
disappearance during anoxia (Fig. 5). Creatine did not
provide a statistically significant effect, even if a not
significant trend toward delay was observed (Fig. 5).Effects after block of the creatine transporter. After
impairment of the creatine transporter with 1 mM GPA
Fig. 5. Time to disappearance of the population spike during anoxia
(the latter was obtained by replacing oxygen with nitrogen in the
incubation chamber). Abbreviations Cr = creatine; Cr/glu-
conate = creatine gluconate; Cr/ascorbate = creatine ascorbate.
Data are mean ± standard deviation. Asterisks above brackets show
statistically significant differences with control group (p< 0.05, post
hoc Dunn’s multiple comparison test). N= 22–26 (min–max in all
groups).
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normal slices (compare controls with GPA in Fig. 6).
This suggests that the block of the creatine transporter
by itself has a deleterious effect on anoxia survival. In
the presence of GPA, creatine monohydrate was againFig. 6. Time to disappearance of the population spike during anoxia (the la
replacing oxygen with nitrogen in the incubation chamber). Abbreviations
propionic acid (blocker of the creatine transporter), Cr = creatine; Cr/g
gluconate; Cr/ascorbate = creatine ascorbate. Data are mean ± standard
above brackets show statistically significant differences with the GPA group
Dunn’s multiple comparison test). N= 14–17 (min–max in all groups).unable to delay PS disappearance, while both creatine
ascorbate and creatine gluconate did delay such
disappearance (Fig. 6).
Table 1 summarizes the above-reported effects of the
different creatine-derived molecules on the various
parameters we investigatedDISCUSSION
Since creatine appears as an internal salt and is only a
relatively weak base, it is rather unusual that stable
creatine salts are formed with acid enols like ascorbic
acid, and with mild organic acids like gluconic acid or
glucose. In all these salts, the non-creatine compound is
transported across biological membranes (BBB and the
cells’ plasma membrane) by a specific transporter. We
hypothesized that the creatine molecule in each of these
salts may be transported across the same biological
membranes together with the linked compound. Such a
mechanism has been demonstrated before for other
molecules (Greer M. Carrier drugs. Presidential address
American Academy of Neurology, 1987. Neurology.
1988 Apr;38(4):628–32). Specifically, with this same
mechanism ascorbic acid has been shown to be an
efficient vector for many pharmaceuticals, transporting
across the BBB antiepileptic, antiviral and antitumoral
compounds (Dalpiaz et al., 2005). Such transport is medi-
ated by SVCT2, the ascorbic acid transporter.
Thus, in principle one or more of the glucose
transporters should carry the creatine glucose salt.




(p< 0.05, post hocfour have been detected in high dose
in brain: GLUTS 1, 3, 5 and 7
(Simpson et al., 1994). GLUT 2
appears to be widely expressed in all
brain regions, but at apparently low
levels, GLUT 4 is expressed in the pitu-
itary, the hypothalamus and the
medulla (Brant et al., 1993). GLUT1
have two isoform: molecular mass
55 kDa present in endothelial cells
and 45 kDa present in the astroglia
and neurons. the concentration of
55 kDa GLUT1 in the BBB, which has
been found by CH binding to be of the
order of 60–80 pmol/mg, with a dissoci-
ation constant (K,) for CH of 0.8 pM in
purified human microvessels (Dick
et al., 1984). GLUT3 is present in cell
membranes that make up cell bodies,
dendrites and axons of neurons its
widespread distribution in neuronal ele-
ments including the neurohypophysis
and cerebellar granule, and its absence
in white matter, adenohypophysis,
pineal gland and cerebral microvessels
(Brant et al., 1993). GLUT5 to be pre-
sent in resident microglial cells, in
macrophages functionally and antigeni-
cally related to microglia. GLUT 7 has
been detected in a certain sub-
Table 1. Summary of the various effects by the compounds we investigated



















Creatine Yes No no Yes No No
Cr-gluconate Yes Yes Yes Yes (more than
creatine itself)
No Yes
Cr-ascorbate Yes YES Yes Yes No Yes
Cr-glucose Yes Yes N/A No No N/A
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over, we hypothesize that D-gluconic acid may be trans-
ported by one or more of the same glucose transporters
(a specific gluconate transporter has been so far found
only in prokaryotes) due to their chemical similarity. By
contrast, ascorbic acid has a specific transporter (Rivas
et al., 2008) that should in theory carry the creatine ascor-
bate salt.
Under normal conditions (Cr transporter working)
exogenous creatine increased creatine intracellular
content as expected (Fig. 3A), although it did not
increase phosphocreatine content (Fig. 3B). The latter
finding may be due to the relatively low concentration of
creatine we used. In fact, Bianchi et al. (2007) demon-
strated that increase of phosphocreatine in the human
brain in vivo is dependent on the dose of exogenous cre-
atine (cf. for example their Fig. 3C). Thus, it is possible
that the 2 mM creatine concentration we used was not
sufficient to increase phosphocreatine in our slices. What-
ever its explanation, lack of phosphocreatine increase in
our experiments was very likely the reason why creatine
in our hands did not delay disappearance of synaptic
transmission during anoxia (Fig. 5), an effect that
Whittingham and Lipton (1981) found after incubating
brain slices with 25 mM creatine.
Under conditions of pharmacologically impaired
transporter (Fig. 4) creatine again increased to an
extent its own tissue content (Fig. 4A). This finding
suggests that GPA caused only an incomplete block of
the transport. This is consistent with what some of us
previously published (Lunardi et al., 2006). In that refer-
ence some of us found that 10 mM GPA reduces to
50% (thus it does not fully prevent) creatine uptake by
brain slices (cf. Fig. 4A of the above reference).
In the present experiments, creatine supplementation
after albeit partial transporter block with GPA did not
increase phosphocreatine concentration (Fig. 4B).
Consequently, and as expected, creatine was not able
to delay PS disappearance during anoxia after
transporter impairment (Fig. 6).
Concerning creatine salts, under normal conditions
(transporter working regularly) all of them increased
creatine content as creatine did (Fig. 3A). However, at
variance with creatine they also significantly increased
tissue phosphocreatine content (Fig. 3B), perhaps
suggesting a better penetration of these compounds
across the cell plasma membrane. We also can
hypothesize that the three compounds are easily
phosphorylated (then probably degraded tophosphocreatine) but not so easily de-phosphorylated.
This is in fact what happens with cyclocreatine, whose
dephosphorylation is slower than phosphorylation
(LoPresti and Cohn, 1989). This would not be surprising,
as in normal conditions these compounds should enter
cells using both creatine and glucose or ascorbate trans-
porters. Alternatively (or additionally), we may speculate
that the presence in the salt of the anionic portion (glucose,
gluconic and ascorbic acid) can also create a protective
shell to the creatine molecule. This protective shell could
prevent or delay transformation of creatine into creatinine.
Thus, creatine would be slowly released being available for
a longer time to the subsequent phosphorylation.
Probably because of the increase in phosphocreatine
they determined, creatine-gluconate and creatine-
ascorbate also delayed the disappearance of evoked
electrical potentials during anoxia (Fig. 5).
Under conditions of transporter impairment, creatine
ascorbate and creatine gluconate increased again the
intracellular content of creatine, while creatine-glucose
did not have such effects (Fig. 4A). Moreover, creatine-
gluconate increased tissue creatine significantly more
than creatine itself did. The latter findings again strongly
suggests that these creatine-derived compounds enter
neurons independently on the Cr transporter. We
hypothesize that creatine gluconate enters the cells
using one or more of the glucose transporters, and that
creatine-ascorbate enters the cells using the SVCT2
(ascorbic acid) transporter. After entry, they are likely
split back to their two constitutive molecules (creatine
and ascorbate, or creatine and gluconate).
Despite being salts, thus dimeric molecules whose
two constituents are not covalently bound, these
compounds decayed slowly is aqueous solution (Fig. 2).
Such a slow decay is consistent with the biological
effects we found.
We do not exclude a partial dissociation of the salts in
two components into ACSF medium. However, this could
possibly explain the electrophysiological effects (Figs. 2
and 3) not the biochemical ones. In fact, these
substances raise the levels of phosphocreatine
significantly, something that creatine alone does not do
(Fig. 4). Moreover, a specific compound (creatine
gluconate) raises the creatine levels more than creatine
itself when the transporter is blocked (Fig. 5). This effect
can be explained only by a better penetration by the
salts, not by a separate entry of the two moieties.
None of the tested salts should be toxic, since in them
creatine is bound to compounds that are used in human
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dietary supplement for humans (Myprotein, Manchester
UK). Thus, these creatine-derived compounds may be
useful in the treatment of hereditary CrT transporter
deficiency. A potential pitfall might be, however, their
route of administration. In fact, being salts they are
likely not absorbed as such by the intestinal mucosa. If
this was the case, they might not reach as salts the
BBB, or they might reach it in an amount insufficient to
provide a biological effect. Further research is needed to
investigate this issue. However, it is likely that a
parenteral way of administration might be necessary.
Alternatively, dimeric molecules where the two
compounds are covalently bound might be effective
even by oral route.CONCLUSIONS
After the creatine transporter was partially impaired by a
submaximal dose of GPA, creatine gluconate is capable
to increase creatine content more than creatine does,
and to delay synaptic failure during anoxia (an effect
that creatine does not have). Therefore, it might be
useful in the therapy of creatine transporter deficiency, a
currently incurable condition. The results we report
justify further research on this topic.EXPERIMENTAL PROCEDURE
Experimental compounds
Creatine monohydrate was purchased from Sigma–
Aldrich (Hercules CA, USA). Creatine gluconate (Fig. 1)
was purchased from Myprotein (Meridian House,
Gadbrook Park, Gadbrook Way, Northwich, UK). HPLC
check of purity yielded >99%.
Creatine-ascorbate and Creatine-glucose was
synthesized following the method described by Pischel
et al. (1999) with some modifications.
The partner compound (ascorbic acid or glucose) and
creatine monohydrate in equivalent molar ratio were
suspended in ethyl acetate protected from light. The
reaction was carried out at room temperature until its
completion monitoring by thin layer chromatography
(TLC). Two eluent phases were used for the TLC:
n-butanol:CH3COOH:H2O (6:2:2) and MeOH:CHCl3:
CH3COOH (8:1.75:0.25). Detection was obtained with a
solution of ninhydrin in ethanol spraying before putting
on hot plate over 100 C.
Then, at the completion of the reaction (about 24 h),
the mixture was filtered and washed twice with ethyl
acetate. The white powder obtained was dried in a
vacuum chamber until dryness. The yield was almost
quantitative.
The final product was finally verified by HPLC–MS
analysis. The qualitative analysis of the products was
finally confirmed by ESI-MS and ESI-MS2 analysis.
Molecular weights were: m/z= 307.2 for creatine-
ascorbate and m/z 311.2 for Creatine-glucose. The
products were used in in vitro experiments without
further purification.Stability in aqueous medium of creatine ascorbate,
creatine gluconate and creatineglucose
To investigate the stability of the three creatine salts,
creatine ascorbate, creatine gluconate and creatine
glucose, the constructs were dissolved at the final
concentration of 2 mM in ACSF at 36 C and the
solutions were diluted 500 times in waters. 10 microliters
of each solution were injected in the MS system by flow
injection analysis (FIA), and the obtained peaks were
quantified. We were interested to know the amount of
creatine ascorbate, creatine gluconate and creatine
glucose that was still intact at time 0 and after 60, 120
and 180 min of treatment. Thus, at these times, the area
under each peak was measured and normalized as a
percentage of the peak area relative to each compound,
at time 0 min.
Preparation of hippocampal slices
Approval to conducting the experiments was obtained
from the Italian Ministry of Health (Ministero della
Salute). Experiments were carried out in compliance with
animal care requirements requested by Italian law (law
D.L. 27.1.1992 n. 116, in agreement with the European
Union directive 86/609/CEE). Hippocampal slices were
prepared in vitro as previously described (Adriano et al.,
2011) In order to isolate the hippocampus, the animal is
anesthetized with ethyl ether and immediately decapi-
tated. After this the left hippocampus is extracted and sub-
divided into transversal slices with respect to the length of
the organ, the slices being 600-lm thick for electrophysio-
logical experiments or 400 lm for biochemical experiment.
The slices thus obtained are transferred into a serum-free
solution of artificial cerebrospinal fluid which is constantly
oxygenated by a mixture of 95% oxygen and 5% carbon
dioxide, in this way maintaining the pH around 7.35–7.4,
and are incubated in a thermostatic bath at a temperature
of 32 C for electrophysiological experiments or 36 C for
biochemical experiment. The artificial cephalorachidian
fluid (ACSF – Artificial Cerebro – Spinal Fluid) is an
aqueous solution made up of the following compounds:
NaCl 130 mM; KCl 3.5 mM; NaH2PO4 1.25 mM; NaHCO
24 mM; CaCl 31.2 mM; MgSO 21.2 mM; Glucosio
410 mM (pH 7.35–7.4)
Inactivation of creatine transporter in hippocampal
slices
To functionally inactivate the creatine transporter we used
guanidinopropionic acid (GPA) as described in our
previous work (Lunardi et al., 2006). We could not use
chloride-free incubation medium as a method to block cre-
atine transporter nor we could use higher concentrations
of GPA (1 Mm for electrophysiological experiments or
10 Mm for biochemical experiment) because under both
treatments (chloride-free incubation or GPA>1 mM) no
electrical activity could be elicited from the slices (prelim-
inary results, not shown). Our previous data showed that
incubation with GPA 1 mM reduced baseline creatine
content by about 50% (Lunardi et al., 2006, Fig. 4) and
reduced uptake of creatine by about the same measure
(Lunardi et al., 2006, Fig. 5A).
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The neuroprotective effect of the compounds deriving
from creatine was studied using electrophysiological
techniques on in vitro hippocampus slices. We followed
a published method (Whittingham and Lipton, 1981) that
we previously used in our laboratory (Balestrino et al.,
1999; Perasso et al., 2008). It is based on Whittingham
and Lipton’s observation, who showed that treatment pre-
vented the irreversible loss of the synaptic transmission in
mouse hippocampal slices during hypoxia, a protective
effect that was attended by sparing of ATP during hypoxia
itself (In the slices that underwent anoxia and treatment
with creatine, the ATP concentration had lowered itself
to 7.9 lmol/gr of proteins while in the control slices to
3.6 lmol/gr of proteins. The pre-anoxic ATP content
was 13.9 lmol/gr of proteins).
To carry out this type of experiment we used 4- week-
old ICR male mice (CD-1) from Harlan farm, as the
experimental model. Hippocampal slices were prepared
following the method shown above. After 3 h of pre-
incubation, the slices were transferred into an incubation
and electrophysiological registering chamber (Fine
Science Tools, Vancouver, Canada). The tissue is
maintained at 35 ± 1 C, with a constant flow (2 ml/min)
of ACSF having the same composition as that in the
incubation medium. After this anoxia is induced by
substituting the oxygen present in gaseous phase in the
incubation chamber with nitrogen, after which the action
potential in the extracellular compound is measured,
stimulating every 5 s. Two tungsten microelectrodes are
positioned on the hippocampal slice, where one (with a
stimulating function) is positioned in the Schaffer
Collaterals, and the other (with a registering function) is
positioned in the CA1 cellular body layer. Once anoxia
is established, the P.S. tends to reduce progressively till
it disappears. The amount of time the signal (P.S.)
takes to disappear from the moment anoxia starts is
registered. The neuroprotective activity of creatine or of
compounds with a similar action as creatine is carried
out by delaying the depletion of ATP during anoxia and
thus delaying the disappearance of the P.S., which is
ATP dependant (Whittingham and Lipton, 1981).
We set up the following experimental groups:
 ACSF.
 ACSF + creatine (2 mM).
 ACSF + the compound to be tested (2 mM).
 ACSF + GPA (1 mM).
 ACSF + GPA (1 mM) + Creatine (2 mM).
 ACSF + GPA (1 mM) + the compound to be tested
(2 mM).
Tissue processing for biochemical experiment
Slices 400- lm-thick were incubated at 36 C in one of the
following media:
 ACSF.
 ACSF + creatine (2 mM).
 ACSF + the compound to be tested (2 mM).
 ACSF + GPA (10 mM). ACSF + GPA (10 mM) + Creatine (2 mM).
 ACSF + GPA (10 mM) + the compound to be tested
(2 mM).
To reduce possible sample variability due to the
slicing procedure, we pooled slices from different
animals before incubation. To this aim, slices from each
animal were distributed among all the incubation
beakers, dropping two slices from that animal in each of
the incubation beakers. Thus, each beaker contained 16
hippocampal slices from ten different animals. Each
beaker was filled with one of the above described
incubation media and was considered as one
experimental subject. After 180 min of incubation at
36 C, slices from each beaker were washed with saline
solution. The incubation times we used are compatible
with an uptake of the three compounds into the tissue.
Whittingham and Lipton (1981) showed that in brain slices
tissue content of phosphocreatine increases linearly over
3-h of incubation with extracellular creatine. Their data
show that even after 1 or 2 h of incubation the tissue
levels of phosphocreatine are elevated above baseline.
Since our compounds have a half-life of 1–2 h, the incu-
bation time we used is compatible with an increased
uptake of our compounds. They were then instantly fro-
zen on the wall of an Eppendorf vial maintained in liquid
nitrogen, and immediately stored at 80 C. Afterward,
the slices from each beaker were homogenized together
in a solution of perchloric acid 0.3 M, to inactivate creatine
kinase. The homogenate obtained was adjusted to pH 7
with potassium carbonate 3 M. Samples were cen-
trifuged. Proteins in the precipitate were evaluated by
bicinchoninic acid assay (Smith et al., 1985) using BCA
Protein Assay Kit (Sigma–Aldrich); all the measures were
performed using bovine serum albumin (BSA) as stan-
dard. The protein concentration was used to normalize
the levels of different metabolites in the supernatant.Tissue content of creatine and phosphocreatine
The quantitative analysis of metabolites was carried out,
with minor modifications, according to a previous
published paper (Lunardi et al., 2006), using
high-performance liquid chromatography (Agilent
1260system – Agilent Technologies, Palo Alto, CA, USA)
equipped with a standard autosampler. Briefly, separa-
tions were performed on a Symmetry C18, 3.9 mm x
150 mm column with 5-lm particle size (Waters Corpora-
tion, Milford, MA, USA) in isocratic mode. The mobile
phase was an aqueous solution of 40 mM sodium phos-
phate dibasic (Na2HPO4) containing 1 mM tetrabutylam-
monium hydrogen sulfate (TBAHS) (solvent A) while the
mobile phase B was an aqueous solution of sodium phos-
phate monobasic (NaH2PO4) 40 mM, TBAHS 1 mM, at pH
6.8. All reagents were of analytical grade (Sigma, St. Louis,
MO, USA). Flow rate was 0.8 ml/min and wavelength was
set to 220 nm. The column temperature was set to 30 C.
Injection volume was 5 ll both for standards and samples.
Standard molecules were diluted in the mobile phase to
reach, time by time, the desired concentration and super-
natant of sample were diluted 1:1 in the mobile phase.
E. Adriano et al. / Neuroscience 340 (2017) 299–307 307The calibration curves, performed in triplicate using three
standard concentrations including the expected values
for samples, were carried out before each set of samples
and accuracy was verified ‘‘in day”. Sample concentrations
were determined using sample peak areas. The accuracy
was in the range of ±13 to ±16% at the tested levels and
the relative standard deviation was in the range of 8% to
12%.
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